BeOne Medicines
ONC
#651
Rank
HK$278.00 B
Marketcap
HK$2,512
Share price
-2.56%
Change (1 day)
55.53%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Revenue for BeOne Medicines (ONC)

Revenue in 2025 (TTM): HK$38.76 Billion

According to BeOne Medicines's latest financial reports the company's current revenue (TTM ) is HK$38.68 Billion. In 2024 the company made a revenue of HK$29.58 Billion an increase over the revenue in the year 2023 that were of HK$19.20 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for BeOne Medicines from 2015 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) HK$38.76 B31.04%
2024 HK$29.58 B54.04%
2023 HK$19.20 B73.58%
2022 HK$11.06 B20.61%
2021 HK$9.17 B283.06%
2020 HK$2.39 B-28.2%
2019 HK$3.33 B114.85%
2018 HK$1.55 B-16.66%
2017 HK$1.86 B22346.94%
2016 HK$8.29 M-87.86%
2015 HK$68.33 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Onconova Therapeutics
ONTX
HK$1.75 M-100.00%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
HK$4.99 B-87.09%๐Ÿ‡บ๐Ÿ‡ธ USA